tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Hemolysis D006461 131 associated lipids
Uremia D014511 33 associated lipids
Colitis, Ulcerative D003093 24 associated lipids
Stomach Ulcer D013276 75 associated lipids
Kidney Failure, Chronic D007676 51 associated lipids
Nocardia Infections D009617 6 associated lipids
Diarrhea D003967 32 associated lipids
Diabetes Mellitus D003920 90 associated lipids
Graft Occlusion, Vascular D006083 11 associated lipids
Hypercalcemia D006934 13 associated lipids
Neovascularization, Pathologic D009389 39 associated lipids
Adenocarcinoma D000230 166 associated lipids
Dermatitis, Contact D003877 59 associated lipids
Bacterial Infections D001424 21 associated lipids
Pain D010146 64 associated lipids
Autoimmune Diseases D001327 27 associated lipids
Lupus Erythematosus, Systemic D008180 43 associated lipids
Genital Diseases, Female D005831 7 associated lipids
Mouth Diseases D009059 5 associated lipids
Meningococcal Infections D008589 3 associated lipids
Lung Diseases D008171 37 associated lipids
Lung Neoplasms D008175 171 associated lipids
Mycobacterium Infections D009164 7 associated lipids
Sarcoidosis D012507 13 associated lipids
Hepatolenticular Degeneration D006527 3 associated lipids
Hyperglycemia D006943 21 associated lipids
Carcinoma, Squamous Cell D002294 14 associated lipids
Skin Neoplasms D012878 12 associated lipids
Burns D002056 34 associated lipids
Inflammation D007249 119 associated lipids
Inflammatory Bowel Diseases D015212 9 associated lipids
Reperfusion Injury D015427 65 associated lipids
Colitis D003092 69 associated lipids
Colonic Neoplasms D003110 161 associated lipids
Diabetes Mellitus, Type 1 D003922 56 associated lipids
Diabetes Mellitus, Type 2 D003924 87 associated lipids
Fatty Liver D005234 48 associated lipids
Cataract D002386 34 associated lipids
Diabetes Mellitus, Experimental D003921 85 associated lipids
Body Weight D001835 333 associated lipids
Edema D004487 152 associated lipids
Precancerous Conditions D011230 48 associated lipids
Postoperative Complications D011183 5 associated lipids
Arthritis D001168 41 associated lipids
Arthritis, Experimental D001169 24 associated lipids
Surgical Wound Infection D013530 7 associated lipids
Neoplasm Recurrence, Local D009364 5 associated lipids
Osteonecrosis D010020 5 associated lipids
Hypotension D007022 41 associated lipids
Acute Kidney Injury D058186 34 associated lipids
Heart Failure D006333 36 associated lipids
Angioedema D000799 6 associated lipids
Fractures, Spontaneous D005598 4 associated lipids
Hydronephrosis D006869 4 associated lipids
Trypanosomiasis D014352 5 associated lipids
Alopecia D000505 14 associated lipids
Liver Diseases D008107 31 associated lipids
Corneal Diseases D003316 13 associated lipids
Testicular Diseases D013733 15 associated lipids
Facial Dermatoses D005148 7 associated lipids
Hypersensitivity D006967 22 associated lipids
Osteosarcoma D012516 50 associated lipids
Acne Vulgaris D000152 35 associated lipids
Urination Disorders D014555 9 associated lipids
Arterial Occlusive Diseases D001157 12 associated lipids
Anemia, Hemolytic D000743 4 associated lipids
Leukemia, Erythroblastic, Acute D004915 41 associated lipids
Vision Disorders D014786 10 associated lipids
Multiple Myeloma D009101 13 associated lipids
Osteochondrodysplasias D010009 3 associated lipids
Melanoma D008545 69 associated lipids
Hematologic Diseases D006402 3 associated lipids
Muscular Dystrophies D009136 10 associated lipids
Osteoporosis D010024 12 associated lipids
Anemia, Aplastic D000741 6 associated lipids
Kidney Diseases D007674 29 associated lipids
Hematuria D006417 13 associated lipids
Weight Gain D015430 101 associated lipids
Brain Diseases D001927 27 associated lipids
Cardiovascular Diseases D002318 24 associated lipids
Infection D007239 6 associated lipids
Abnormalities, Multiple D000015 13 associated lipids
Hypersensitivity, Delayed D006968 43 associated lipids
Glioma D005910 112 associated lipids
Cell Transformation, Neoplastic D002471 126 associated lipids
Bone Diseases D001847 4 associated lipids
Leukemia P388 D007941 43 associated lipids
Ulcer D014456 16 associated lipids
Hypercholesterolemia D006937 91 associated lipids
Obesity D009765 29 associated lipids
Thrombosis D013927 49 associated lipids
Bradycardia D001919 13 associated lipids
Hemorrhage D006470 15 associated lipids
Proteinuria D011507 30 associated lipids
Lymphoma D008223 18 associated lipids
Femur Head Necrosis D005271 5 associated lipids
Alzheimer Disease D000544 76 associated lipids
Drug Hypersensitivity D004342 20 associated lipids
Eye Diseases D005128 12 associated lipids
Arteriosclerosis D001161 86 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Watanabe K et al. Donor bone marrow cell facilitates induction of tolerance to kidney allografts in dogs treated with fractionated lymphoid irradiation and FK 506. 1991 Transplant. Proc. pmid:1703706
Thomson AW Interspecies comparison of the immunosuppressive efficacy and safety of FK 506. 1990 Transplant. Proc. pmid:1689883
Khalaf H et al. Tacrolimus (FK 506) given three times daily after liver transplantation for minimizing nephrotoxicity and neurotoxicity. 2003 Transplant. Proc. pmid:14612120
Fougeray S et al. Increased body mass index after kidney transplantation in activating transcription factor 6 single polymorphism gene carriers. 2011 Transplant. Proc. pmid:22099811
Kumar MS et al. ATGAM versus OKT3 induction therapy in cadaveric kidney transplantation: patient and graft survival, CD3 subset, infection, and cost analysis. 1998 Transplant. Proc. pmid:9636549
Yu L et al. Clinical experience with Prograf (tacrolimus, FK 506) in Chinese patients after renal transplantation. 2000 Transplant. Proc. pmid:11119902
Neylan JF Effect of race and immunosuppression in renal transplantation: three-year survival results from a US multicenter, randomized trial. FK506 Kidney Transplant Study Group. 1998 Transplant. Proc. pmid:9636551
Tanabe K et al. ABO-incompatible living donor kidney transplantation under tacrolimus immunosuppression. 2000 Transplant. Proc. pmid:11119903
Corry RJ et al. Tacrolimus without antilymphocyte induction therapy prevents pancreas loss from rejection in 123 consecutive patients. 1998 Transplant. Proc. pmid:9532157
Elmer DS et al. Metabolic effects of FK 506 (tacrolimus) versus cyclosporine in portally drained pancreas allografts. 1998 Transplant. Proc. pmid:9532159
Berman M et al. Lipid metabolism and immunosuppressive therapy in heart transplant recipients. 2003 Transplant. Proc. pmid:12644091
Marcén R et al. Evolution of rejection rates and kidney graft survival: a historical analysis. 2009 Jul-Aug Transplant. Proc. pmid:19715918
Lauzurica R et al. Monotherapy with tacrolimus and corticosteroid withdrawal. 2002 Transplant. Proc. pmid:11959217
Stephens J et al. Effects of orthotopic liver transplantation and immunosuppression on inflammatory bowel disease in primary sclerosing cholangitis patients. 1993 Transplant. Proc. pmid:7680144
Sumpio BE and Phan S Nephrotoxic potential of FK 506. 1991 Transplant. Proc. pmid:1721278
Fukushima N et al. Histological findings in heart grafts after orthotopic pig to baboon cardiac transplantation. 1996 Transplant. Proc. pmid:8623400
Takada Y et al. Improvement of allograft viability with organs procured from non-heart-beating donors in porcine liver transplantation. 2000 Transplant. Proc. pmid:10715416
Land W et al. Mycophenolate mofetil monotherapy: an optimal, safe, and efficacious immunosuppressive maintenance regimen in kidney transplant patients. 2001 Transplant. Proc. pmid:11406265
Charco R et al. Hypercholesterolemia in long-term survivors of liver transplantation: a comparison between cyclosporine and FK 506. 1998 Transplant. Proc. pmid:9636605
Jang HJ et al. Comparison of pancreas transplantation outcome between the cyclosporine and tacrolimus eras. 2000 Transplant. Proc. pmid:11120249
Squifflet JP et al. The Benelux experience with the combination of tacrolimus and mycophenolate mofetil. 1999 Transplant. Proc. pmid:10576050
Morales JM et al. Tacrolimus, mycophenolate mofetil and corticosteroids as primary immunosuppression after renal transplantation at the Hospital 12 de Octubre, Madrid. 1999 Transplant. Proc. pmid:10576051
Tekgündüz E et al. Electrolyte free water clearance could be an early sign of renal dysfunction in renal transplant patients. 2009 Transplant. Proc. pmid:19917375
Mano A et al. Reversible myocardial hypertrophy induced by tacrolimus in a pediatric heart transplant recipient: case report. 2009 Transplant. Proc. pmid:19917396
Furlan V et al. Interaction between tacrolimus and itraconazole in a heart-lung transplant recipient. 1998 Transplant. Proc. pmid:9474996
Lampreabe I et al. Toward personalized medicine in renal transplantation. 2010 Transplant. Proc. pmid:20970553
Zawiasa A et al. Effect of oral fructose load on serum uric acid and lipids in kidney transplant recipients treated with cyclosporine or tacrolimus. 2009 Jan-Feb Transplant. Proc. pmid:19249511
Sato K et al. Management of living donor liver transplant patients using twice-daily 4-hour intravenous cyclosporine therapy. 2009 Jan-Feb Transplant. Proc. pmid:19249521
Nishimori H et al. Combination therapy with FK 506 and splenectomy may induce tolerance in cardiac xenografts. 1994 Transplant. Proc. pmid:7518102
Schwartz M et al. FK 506 in liver transplantation: correlation of whole blood levels with efficacy and toxicity. The US Multicenter FK 506 Dose Optimization. 1995 Transplant. Proc. pmid:7533355
Yasuhara M et al. Pharmacokinetics and pharmacodynamics of FK 506 in pediatric patients receiving living-related donor liver transplantations. 1995 Transplant. Proc. pmid:7533356
de Paulis A et al. Antiinflammatory effect of FK 506 on human basophils. 1991 Transplant. Proc. pmid:1721309
Su MS and Semerjian A Activation of transcription factor NF kappa B in Jurkat cells is inhibited selectively by FK 506 in a signal-dependent manner. 1991 Transplant. Proc. pmid:1721310
Iga C et al. Prolonged survival of small intestinal allograft in the rat with cyclosporine A, FK 506, and 15-deoxyspergualin. 1990 Transplant. Proc. pmid:1697118
Kuriata-Kordek M et al. The influence of calcineurin inhibitors on mycophenolic acid pharmacokinetics. 2003 Transplant. Proc. pmid:14529944
Chiang Y et al. Posttransplantation Kaposi sarcoma-experience in a patient receiving FK-506 and MMF. 2003 Transplant. Proc. pmid:12591389
Borrows R et al. Tacrolimus monitoring in renal transplantation: a comparison between high-performance liquid chromatography and immunoassay. 2005 Transplant. Proc. pmid:15919448
Grochowicz PM et al. Synergism of castanospermine and FK 506. 1995 Transplant. Proc. pmid:7533408
Reding R et al. Compassionate use of FK 506 in pediatric liver transplantation: a pilot study. 1991 Transplant. Proc. pmid:1721341
Lee KK et al. Comparison of short-term immunosuppressive therapy with cyclosporine and FK 506 in small-bowel transplantation. 1990 Transplant. Proc. pmid:1702239
Charco R et al. Changes in renal function in long-term survivors of liver transplantation: a comparison between cyclosporine microemulsion and tacrolimus therapy. 2002 Transplant. Proc. pmid:12176478
Aguirrezabalaga J et al. Lipid profiles after liver transplantation in patients receiving tacrolimus or cyclosporin. 2002 Transplant. Proc. pmid:12176480
Yokoyama I et al. Immunosuppressant effect on Fas antigen expression and p53 of an experimental tumor. 1998 Transplant. Proc. pmid:9865346
Gerauer K et al. Long-term cardiac allograft survival in mice treated with malononitrilamide 715. 1998 Transplant. Proc. pmid:9865349
Hossain MA et al. Immunosuppression in auxiliary partial liver transplantation with FK506 in rats. 1997 Transplant. Proc. pmid:9414861
Bortman GV et al. South American Heart Transplantation Registry of patients receiving everolimus in their immunosuppressive regimens. 2010 Jan-Feb Transplant. Proc. pmid:20172342
Parada MT et al. Everolimus in lung transplantation in Chile. 2010 Jan-Feb Transplant. Proc. pmid:20172343
Strassburg A et al. Basiliximab reduces acute liver allograft rejection in pediatric patients. 2002 Transplant. Proc. pmid:12270443
Rifai K et al. Severe hearing loss after liver transplantation. 2005 Transplant. Proc. pmid:15919504
Weimer R et al. Effects of three immunosuppressive regimens on CD4 helper function, B cell monocyte and cytokine responses in renal transplant recipients: 4-month follow-up of a prospective randomized study. 2002 Transplant. Proc. pmid:12270445
Oltean M et al. FK506 donor pretreatment improves intestinal graft microcirculation and morphology by concurrent inhibition of early NF-kappaB activation and augmented HSP72 synthesis. 2005 Transplant. Proc. pmid:15919508
Ciftci HS et al. Effect of MDR1 polymorphisms on the blood concentrations of tacrolimus in Turkish renal transplant patients. 2013 Transplant. Proc. pmid:23622581
Miller J et al. FK 506 in kidney transplantation: results of the U.S.A. randomized comparative phase III study. The FK 506 Kidney Transplant Study Group. 1997 Feb-Mar Transplant. Proc. pmid:9123008
Jordan ML et al. Five-year experience with tacrolimus rescue for renal allograft rejection. 1997 Feb-Mar Transplant. Proc. pmid:9123009
Kilinç M et al. FK 506-induced fulminant leukoencephalopathy after kidney transplantation: case report. 2002 Transplant. Proc. pmid:12072309
Toyama Y et al. Prolonged small bowel graft survival using photochemotherapy and low-dose FK 506. 1996 Transplant. Proc. pmid:8907924
Takahashi K et al. Successful results after 3 years' tacrolimus immunosuppression in ABO-incompatible kidney transplantation recipients in Japan. 2002 Transplant. Proc. pmid:12176502
Fahlke J et al. Staggered immunosuppression with the interleukin-2 receptor antagonist daclizumab combined with tacrolimus, prednisolone, and mycophenolate mofetil after orthotopic liver transplantation: a pilot efficacy and safety study. 2002 Transplant. Proc. pmid:12072328
Yamada T et al. Synergistic effect of FK 506 and trifluoperazine on the immunosuppression in rat small bowel transplantation. 1996 Transplant. Proc. pmid:8907927
Uchida K et al. Excellent 3-year results following living-donor kidney transplantation and tacrolimus immunosuppression in Japan. 2002 Transplant. Proc. pmid:12176503
Calia R et al. Effects of switching from twice-daily to once-daily tacrolimus formulation on quality of life, anxiety, and transplant benefit perception after kidney transplantation. 2011 Transplant. Proc. pmid:21620041
Chen CL et al. FK 506 used as rescue therapy for refractory liver allograft rejection. 1994 Transplant. Proc. pmid:7520612
Nakata S et al. Immunosuppressive mechanisms of deoxymethylspergualin and FK 506 on in vitro cytotoxic T lymphocytes. 1994 Transplant. Proc. pmid:7520613
Deuse T et al. Is the malononitrilamide FK778 better for the prevention of acute or chronic rejection? 2007 Transplant. Proc. pmid:17362784
Hebert MF et al. Efficacy and toxicity of FK 506 for the treatment of resistant rejection in liver transplant patients. 1991 Transplant. Proc. pmid:1721373
Eiras G et al. Effects of FK 506 and cyclosporine on T-cell activation: integrin-mediated adhesion of T cells, proliferation, and maturation of cytotoxic T cells. 1991 Transplant. Proc. pmid:1703357
Clinicopathological evaluation of kidney transplants in patients given a fixed dose of FK 506. Japanese FK 506 Study Group. 1991 Transplant. Proc. pmid:1721374
Christians U et al. Measurement of FK 506 by HPLC and isolation and characterization of its metabolites. 1991 Transplant. Proc. pmid:1703358
Shapiro R et al. Reversibility of tacrolimus-induced posttransplant diabetes: an illustrative case and review of the literature. 1997 Transplant. Proc. pmid:9290809
Kumano K et al. Role of the transforming growth factor and monocyte chemoattractant protein in FK506-induced nephropathy in the rat. 1997 Feb-Mar Transplant. Proc. pmid:9123293
Braun F et al. Pharmacokinetics of tacrolimus primary immunosuppression in kidney transplant recipients. 2001 Transplant. Proc. pmid:11377473
Wilczek HE et al. Renal transplant histopathologic changes during the first year in patients with tacrolimus (FK 506). 1996 Transplant. Proc. pmid:8962232
Saito K et al. Study of pharmacokinetic parameters of tacrolimus by different oral administration periods in renal transplantation. 2002 Transplant. Proc. pmid:12176553
Toraishi T et al. Falsely abnormally elevated blood trough concentration of tacrolimus measured by antibody-conjugated magnetic immunoassay in a renal transplant recipient: a case report. 2012 Transplant. Proc. pmid:22310597
Lee PC et al. Cyclosporine or tacrolimus: which is the better partner for myfortic or cellcept? 2012 Transplant. Proc. pmid:22310598
Abu-Elmagd KM et al. Acute hemolytic anemia in liver and bone marrow transplant patients under FK 506 therapy. 1991 Transplant. Proc. pmid:1721404
Yamada K et al. FK 506-induced juxtaglomerular apparatus hyperplasia and tubular damage in rat kidney--morphologic and biologic analysis. 1992 Transplant. Proc. pmid:1379756
Melter M et al. Successful reconversion from tacrolimus to cyclosporine A Neoral in pediatric liver recipients. 1996 Transplant. Proc. pmid:8769224
Ishibashi M et al. Immunopharmacologic effects of immunosuppressive agents explored by a new effector monocyte generation assay. 1989 Transplant. Proc. pmid:2469228
Ettenger R The practical problems of prednisone in pediatric renal transplantation. 2001 Feb-Mar Transplant. Proc. pmid:11267159
Berloco P et al. Tacrolimus as cornerstone immunosuppressant in kidney transplantation. 2001 Feb-Mar Transplant. Proc. pmid:11267161
Takahashi Y et al. Pharmacokinetic Profile of Twice- and Once-daily Tacrolimus in Pediatric Kidney Transplant Recipients. Transplant. Proc. pmid:28104153
Shi Y et al. Comparison of Mizoribine and Mycophenolate Mofetil With a Tacrolimus-Based Immunosuppressive Regimen in Living-Donor Kidney Transplantation Recipients: A Retrospective Study in China. Transplant. Proc. pmid:28104150
Alkhunaizi AM et al. Breast fibroadenomas in renal transplant recipients. 2004 Jul-Aug Transplant. Proc. pmid:15350492
Boletis J et al. Delayed renal graft function: the influence of immunosuppression. 2005 Transplant. Proc. pmid:15964337
Alberti D et al. Conversion from tacrolimus to microemulsion formulation of cyclosporine in pediatric liver transplantation. 1998 Transplant. Proc. pmid:9723310
Russ GR et al. Reduced and standard target concentration tacrolimus with sirolimus in renal allograft recipients. 2003 Transplant. Proc. pmid:12742480
Ciancio G et al. Effect of daclizumab, tacrolimus, and mycophenolate mofetil in pediatric first renal transplant recipients. 2002 Transplant. Proc. pmid:12176637
Rayhill SC et al. A cyclosporine-based immunosuppressive regimen may be better than tacrolimus for long-term liver allograft survival in recipients transplanted for hepatitis C. 2006 Transplant. Proc. pmid:17175350
Kuroki H et al. Synergistic effect of FK 506 and donor-specific blood transfusion on rat skin but not on composite tissue (limb) allograft survival. 1991 Transplant. Proc. pmid:1721436
Todo S et al. Orthotopic liver transplantation in dogs receiving FK-506. 1987 Transplant. Proc. pmid:2445079
Mueller AR et al. Influence of immunosuppression on patient survival after liver transplantation for hepatitis C. 2001 Feb-Mar Transplant. Proc. pmid:11267321
Krämer BK et al. Efficacy of Prolonged- and Immediate-release Tacrolimus in Kidney Transplantation: A Pooled Analysis of Two Large, Randomized, Controlled Trials. 2017 Transplant. Proc. pmid:29149958
Cofan F et al. Fatty acid composition in low-density lipoproteins from renal transplant recipients. 1999 Transplant. Proc. pmid:10500603
Cofan F et al. Oxidation of low-density lipoproteins in renal transplant recipients. 1999 Transplant. Proc. pmid:10500604
Uemoto S et al. Safety and efficacy of once-daily modified-release tacrolimus in liver transplant recipients: a multicenter postmarketing surveillance in Japan. 2014 Transplant. Proc. pmid:24767340
Calne RY Immunosuppression for organ grafting. 1991 Transplant. Proc. pmid:1714646
García-Bello JA et al. Effect of Immunosuppressive Therapy on Cardiovascular Risk Factor Prevalence in Kidney-Transplanted Children: Comparative Study. 2016 Transplant. Proc. pmid:27110020
Braun F et al. Primary low-dose tacrolimus immunosuppressive prophylaxis for high-risk kidney transplant recipients. 1998 Transplant. Proc. pmid:9636496
Stratta RJ et al. Preliminary experience with FK 506 in pancreas transplant recipients. 1995 Transplant. Proc. pmid:8539823